JAMES ROBERT ALLEN
Pilots at 38 Ave, Seattle, WA
License number
Washington A3893715
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
4512 38Th Ave S, Seattle, WA 98118
Professional information
President At Dimensional Products Corp.
Position:
President at Dimensional Products Corp.
Location:
Greater Seattle Area
Industry:
Graphic Design
Work:
Dimensional Products Corp.
since Aug 1985
-
President
Calcom
May 1969 - Aug 1985
-
Vice President
Education:
Western Washington University 1960 - 1965
B of A , B of A, Education,
B of A , B of A, Education,
James Allen - Seattle, WA
Work:
Prison Health Services
Health Service Administrator Provider Advantage
Account Manager Regence BlueShield
Associate Sales and Account Executive, National and Large Accounts
Health Service Administrator Provider Advantage
Account Manager Regence BlueShield
Associate Sales and Account Executive, National and Large Accounts
Education:
Mesa Community College - San Diego, CA
general education
general education
Grand Poopah At Onmyown
Position:
grand poopah at onmyown
Location:
Greater Seattle Area
Industry:
Arts and Crafts
Work:
onmyown
-
grand poopah
Owner At Allen's Sales And Service
Position:
Owner at Allen's Sales And Service
Location:
Greater Seattle Area
Industry:
Internet
Work:
Allen's Sales And Service
-
Owner
Owner At Woodshed Multimedia
Position:
owner at Woodshed Multimedia
Location:
Greater Seattle Area
Industry:
Computer & Network Security
Work:
Woodshed Multimedia
-
owner
Hybrid Genes For Expression Of Stimulatory Factors In Activated T Cells
US Patent:
6593124, Jul 15, 2003
Filed:
Dec 16, 1998
Appl. No.:
09/213993
Inventors:
Stephen D. Lupton - Seattle WA
James M. Allen - Seattle WA
Andrew L. Feldhaus - Lynwood WA
James M. Allen - Seattle WA
Andrew L. Feldhaus - Lynwood WA
Assignee:
Targeted Genetics Corporation - Seattle WA
International Classification:
C12N 121
US Classification:
4352523, 43525411, 435325, 4353201, 536 231, 536 234, 536 235, 536 2352, 536 241
Abstract:
Recombinant vectors are provided that render the proliferative response of activated lymphocytes, particularly cytotoxic T lymphocytes, of lessened dependency on T helper cells. The vectors are comprised of a region encoding a stimulatory factor polypeptide operably linked to a heterologous transcriptional control region. Expression of the stimulatory factor polypeptide from the recombinant polynucleotide in an activated lymphocyte renders the proliferative response of less dependent on lymphocyte T helper cells. When the lymphocyte is activated by binding of its cognate antigen the transcriptional control region causes transcription of the stimulatory factor encoding region. The cells containing the vector, particularly CTLs, are of use in immunotherapy.
Hybrid Genes For Use In The Production Of T.sub.h -Independent Cytotoxic T Cells
US Patent:
5874556, Feb 23, 1999
Filed:
Jun 6, 1994
Appl. No.:
8/244548
Inventors:
Stephen D. Lupton - Seattle WA
James M. Allen - Seattle WA
Andrew L. Feldhaus - Lynwood WA
James M. Allen - Seattle WA
Andrew L. Feldhaus - Lynwood WA
Assignee:
Targeted Genetics Corporation - Seattle WA
International Classification:
C12N 1500, C12N 1524, C12N 1587, A61K 4800
US Classification:
536 231
Abstract:
Recombinant vectors are provided that render the proliferative response of activated lymphocytes, particularly cytotoxic T lymphocytes, of lessened dependency on T-helper cells. The vectors are comprised of a region encoding a stimulatory factor polypeptide operably linked to a heterologous transcriptional control region. Expression of the stimulatory factor polypeptide from the recombinant polynucleotide in an activated lymphocyte renders the proliferative response of less dependent on lymphocyte T-helper cells. When the lymphocyte is activated by binding of its cognate antigen the transcriptional control region causes transcription of the stimulatory factor encoding region. The cells containing the vector, particularly CTLs, are of use in immunotherapy.
Packaging Cell Lines For Generation Of High Titers Of Recombinant Aav Vectors
US Patent:
6924128, Aug 2, 2005
Filed:
Dec 6, 2000
Appl. No.:
09/731941
Inventors:
James M. Allen - Seattle WA, US
Assignee:
Targeted Genetics Corporation - Seattle WA
International Classification:
C12N015/64, C12N015/864
US Classification:
435 914, 424 932, 4353201, 435325, 435455, 435456, 435457, 435352, 435366, 435370, 435367
Abstract:
AAV vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantities of such recombinant vectors in amounts that would be clinically useful for human gene therapy application. Stable AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and can negatively affect the host cell. This invention provides packaging systems and processes for packaging AAV vectors that effectively circumvent these problems and that allow for substantially increased packaging efficiency.
High Input Impedance Buffer With Low Feedback Resistance
US Patent:
5332963, Jul 26, 1994
Filed:
Jun 15, 1993
Appl. No.:
8/077970
Inventors:
Marshall L. Hightower - Mountlake Terrace WA
James F. Allen - Seattle WA
James F. Allen - Seattle WA
Assignee:
John Fluke Mfg. Co., Inc. - Everett WA
International Classification:
G01R 130, G01R 1508
US Classification:
324123R
Abstract:
A high input impedance AC buffer for use in an instrument that does not require high frequency compensation or calibration. An op-amp receives an input signal that is to be measured via a high resistance input resistor and produces an output signal proportional to the input signal. A feedback resistor block and a feedback attenuator form the feedback path of the buffer and establish buffer gain. The low resistances of the feedback block and the feedback attenuator are substantially less than the resistance of the high resistance input resistor, precluding the need for compensation and calibration capacitors. A switching circuit operates to select resistors in the feedback resistance block and the feedback attenuator to provide predetermined gains for the buffer.
Compositions And Methods For Systemic Nucleic Acid Sequence Delivery
US Patent:
7655467, Feb 2, 2010
Filed:
Nov 15, 2004
Appl. No.:
10/988723
Inventors:
Jeffrey S. Chamberlain - Seattle WA, US
Michael J. Blankinship - Seattle WA, US
James M. Allen - Seattle WA, US
Michael J. Blankinship - Seattle WA, US
James M. Allen - Seattle WA, US
Assignee:
The University of Washington - Seattle WA
International Classification:
C12N 15/86, A61K 48/00, A61K 31/70
US Classification:
435456, 424 932, 514 44
Abstract:
The present invention provides systemic nucleic acid sequence delivery without conventional systemic administration aids (SAAs). In certain embodiments, vascular permeability agents (VPAs), such as VEGF, are used in conjunction with nucleic acid viral vectors, such as adeno-associated virus (AAV). The present invention also provides methods of treating disease by co-administration of nucleic cid sequences encoding Igf-1 and dystrophin or dystrophin-like proteins.